News | 09.29.19
REMEDIAL III Shows UFR-Guided Hydration Reduces Risk of Contrast-Induced Kidney Injury in High-Risk Patients
September 29, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the REMEDIAL III trial were presented by Carlo Briguori, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
News | 06.17.19
Merit Medical Acquires Brightwater Medical
June 17, 2019—Merit Medical Systems, Inc. announced that it has acquired Brightwater Medical, Inc. The transaction consists of a $35 million upfront payment and potential earn-out payments of up to $15 million based on receipt of CE Mark approval and achievement of future sales targets.
News | 05.22.19
Studies Support Medtronic's Renal Denervation System in High-Risk Hypertensive Patients
May 22, 2019—Medtronic announced that late-breaking clinical data from a physician-sponsored clinical trial using the company's Symplicity renal denervation (RDN) system were presented at EuroPCR held May 21–24 in Paris, France.
News | 03.20.19
News | 11.08.18
FDA Approves SPYRAL HTN-ON MED Study of Medtronic's Symplicity Spyral RDN System
November 8, 2018—Medtronic announced FDA approval to begin a clinical trial to evaluate the company's Symplicity Spyral renal denervation (RDN) system in patients with uncontrolled blood pressure taking multiple antihypertensive medications.
News | 04.09.18
FDA Approves Medtronic's Pivotal Trial to Evaluate Renal Denervation to Treat Hypertension
April 9, 2018—Medtronic announced US Food and Drug Administration approval to begin an investigational device exemption pivotal trial to evaluate the company's Symplicity Spyral renal denervation system in patients with hypertension.
News | 11.21.17
PRESERVE Trial Indicates No Benefit for Sodium Bicarbonate or Acetylcysteine for Patients With Impaired Kidney Function Undergoing Angiography
November 21, 2017—New data from the PRESERVE clinical trial suggests intravenous sodium bicarbonate has no clinical benefit over the use of intravenous sodium chloride, or of oral acetylcysteine over placebo, for the prevention of death, need for dialysis, or persistent decline in kidney function at 90 days or for the prevention of contrast-associated acute kidney injury, among high-risk patients for renal complications undergoing angiography.
News | 04.06.17
Temporal Trends in Peripheral Artery Interventions Analyzed in BMC2 PVI Registry
April 6, 2017—Findings from a study that aimed to examine trends in procedural indications, arterial beds treated, and device usage in peripheral artery interventions were published by Michael P. Thomas, MD, et al in Catheterization and Cardiovascular Interventions (CCI; 2017;89:726–734).
News | 11.02.16
ReCor Medical Updates Progress in Trials for Paradise Renal Denervation System
November 2, 2016—ReCor Medical, Inc. recently announced key milestones in its RADIANCE-HTN clinical trial to evaluate the effect of the ReCor Paradise renal denervation system on blood pressure in patients with hypertension.
News | 10.12.16
FDA Clears Teleflex's Arrow JACC With Chloragard Technology and Tunneler
October 12, 2016—Teleflex Incorporated announced that it has received US Food and Drug Administration 510(k) clearance to market the company’s Arrow JACC (jugular axillosubclavian central catheter) with Chloragard technology and TightTrack tunneler.
News | 08.10.16
Study Evaluates Treatment of In-Stent Restenosis in Patients With Renal Artery Stenosis
August 10, 2016—Edwin A. Takahashi, MD, et al published findings from a study conducted to determine clinical outcomes of the treatment of patients for renal artery in-stent restenosis (ISR) with atherosclerotic renal artery stenosis. The study is available online ahead of print in the Journal of Vascular and Interventional Radiology (JVIR).
News | 03.29.16
First Use of Bluegrass Surfacer Inside-Out Access Catheter System Performed in Europe
March 29, 2016—Bluegrass Vascular Technologies, Inc. announced today that its Surfacer Inside-Out access catheter system was successfully used on a patient facing life-threatening complications from end-stage renal disease.
News | 02.16.16
Ablative Solutions Commences European Peregrine Postmarket Study for Renal Denervation
February 16, 2016—Ablative Solutions, Inc. announced that Professors Wojtek Wojakowski, MD, and Mariusz Hochul, MD, have treated the first two patients in the European Peregrine postmarket study, which is enrolling patients to receive targeted therapy using the company’s CE Mark-approved Peregrine system infusion catheter with a neurolytic agent to treat sympathetic nerves located in the outer layer of the renal arteries.
News | 01.12.16
Study Evaluates Treatment of Isolated RAAs in Endovascular Era
January 12, 2016—Findings from a study on the management and outcomes of isolated renal artery aneurysms (RAAs) in the endovascular era were published by Dominique B. Buck, MD, et al in the Journal of Vascular Surgery (JVS; 2016;63:77–81). The background of the study is that isolated RAAs are rare, and controversy remains about indications for surgical repair; however, little is known about the impact of endovascular therapy on patient selection and outcomes.
News | 08.03.15
Vascular Solutions Announces Launch of 0.035-Inch Catheters for PolarCath System
August 3, 2015—Vascular Solutions, Inc. announced the expansion of the PolarCath peripheral dilatation system product line with the launch of 11 versions of the 0.035-inch guidewire-compatible balloon catheters, which are manufactured by NuCryo Vascular LLC.
Sponsored by Boston Scientific Corporation
Article | June 2015
News | 04.30.15
Enrollment Begins for Medtronic's SYMPLICITY AF Study of Pulmonary Vein Isolation Combined With Renal Denervation to Treat Atrial Fibrillation
April 30, 2015—Medtronic plc announced the start of the SYMPLICITY AF clinical study using the company’s technologies to determine whether paroxysmal and persistent atrial fibrillation (AF) can be treated with a combination of two ablation procedures targeting different anatomical locations: the pulmonary veins and the renal arteries.
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available vascular interventional devices in Europe.